Adaptative Radiotherapy to Decrease Xerostomia in Oropharynx Carcinoma (ARTIX)
Phase III Trial Testing the Benefit of Intensity-modulated Radiotherapy With Weekly Replanifications Versus Intensity Modulated Radiotherapy With Only One Planification in Locally Advanced Oropharynx Carcinoma for Decreasing Xerostomia
Sponsor: Center Eugene Marquis
A PHASE3 clinical study on Oropharynx Cancer, this trial is completed. The trial is conducted by Center Eugene Marquis and has accumulated 9 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Sep 2021 — Jul 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE3
-
Feb 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
▶ Show 4 earlier versions
-
Mar 2019 — Feb 2020 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Mar 2019 [monthly]
Recruiting PHASE3
-
Dec 2017 — Jun 2018 [monthly]
Recruiting PHASE3
-
Jan 2017 — Dec 2017 [monthly]
Recruiting PHASE3
First recorded
Jul 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Center Eugene Marquis
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Albi, France , Brest, France , Caen, France , Lille, France , Lyon, France , Nice, France , Poitiers, France , Rennes, France , Rouen, France , Strasbourg, France and 1 more location